DE3751404D1 - Verwendung von heterocyclischen Verbindungen zur Behandlung von Bewusstseinsstörungen. - Google Patents

Verwendung von heterocyclischen Verbindungen zur Behandlung von Bewusstseinsstörungen.

Info

Publication number
DE3751404D1
DE3751404D1 DE3751404T DE3751404T DE3751404D1 DE 3751404 D1 DE3751404 D1 DE 3751404D1 DE 3751404 T DE3751404 T DE 3751404T DE 3751404 T DE3751404 T DE 3751404T DE 3751404 D1 DE3751404 D1 DE 3751404D1
Authority
DE
Germany
Prior art keywords
treatment
heterocyclic compounds
consciousness disorders
disorders
consciousness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3751404T
Other languages
English (en)
Other versions
DE3751404T2 (de
Inventor
Michael Brian Tyers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB868630077A external-priority patent/GB8630077D0/en
Priority claimed from GB868630076A external-priority patent/GB8630076D0/en
Priority claimed from GB868630074A external-priority patent/GB8630074D0/en
Priority claimed from GB878707175A external-priority patent/GB8707175D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of DE3751404D1 publication Critical patent/DE3751404D1/de
Application granted granted Critical
Publication of DE3751404T2 publication Critical patent/DE3751404T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE3751404T 1986-12-17 1987-12-16 Verwendung von heterocyclischen Verbindungen zur Behandlung von Bewusstseinsstörungen. Expired - Lifetime DE3751404T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB868630077A GB8630077D0 (en) 1986-12-17 1986-12-17 Medicaments
GB868630076A GB8630076D0 (en) 1986-12-17 1986-12-17 Medicaments
GB868630074A GB8630074D0 (en) 1986-12-17 1986-12-17 Medicaments
GB878707175A GB8707175D0 (en) 1987-03-25 1987-03-25 Medicaments

Publications (2)

Publication Number Publication Date
DE3751404D1 true DE3751404D1 (de) 1995-08-17
DE3751404T2 DE3751404T2 (de) 1995-12-21

Family

ID=27449858

Family Applications (2)

Application Number Title Priority Date Filing Date
DE3752062T Expired - Lifetime DE3752062T2 (de) 1986-12-17 1987-12-16 Verwendung von heterozyklischen Derivaten zur Herstellung von Arzneimitteln
DE3751404T Expired - Lifetime DE3751404T2 (de) 1986-12-17 1987-12-16 Verwendung von heterocyclischen Verbindungen zur Behandlung von Bewusstseinsstörungen.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE3752062T Expired - Lifetime DE3752062T2 (de) 1986-12-17 1987-12-16 Verwendung von heterozyklischen Derivaten zur Herstellung von Arzneimitteln

Country Status (7)

Country Link
US (1) US4985437A (de)
EP (3) EP0559297B1 (de)
JP (1) JP2608079B2 (de)
AT (2) ATE152623T1 (de)
DE (2) DE3752062T2 (de)
ES (1) ES2074981T3 (de)
GR (1) GR3017369T3 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3777805D1 (de) * 1986-11-21 1992-04-30 Glaxo Group Ltd Arzneimittel zur behandlung oder vorbeugung des entzugssyndromes.
US5198447A (en) * 1986-11-21 1993-03-30 Glaxo Group Limited Medicaments
GB8820651D0 (en) * 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
AU5650890A (en) * 1989-05-24 1990-12-18 Nippon Shinyaku Co. Ltd. Indole derivatives and medicine
US5171745A (en) * 1990-07-13 1992-12-15 Du Pont Merck Pharmaceutical Company Method of treating neurological dysfunction using neutrotransmitter enhancers
WO1992004347A1 (fr) * 1990-08-31 1992-03-19 Nippon Shinyaku Co., Ltd. Derive d'indole et medicament
HU211081B (en) * 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
EP0492020A1 (de) * 1990-12-21 1992-07-01 Merrell Dow Pharmaceuticals Inc. Verwendung von bestimmten Estern von Hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-on und verwandter Verbindungen zur Behandlung von kognitiven Erkrankungen
IT1250629B (it) * 1991-07-04 1995-04-21 Boehringer Ingelheim Italia Uso dei derivati dell'acido benzimidazolin-2-oxo-1-carbossilico.
EP0688216A1 (de) * 1993-03-08 1995-12-27 Fujisawa Pharmaceutical Co., Ltd. Medikament zur behandlung und prävention von zerebrovaskulären erkrankungen
GB9412995D0 (en) * 1994-06-28 1994-10-26 Prendergast Kenneth F Safety enhancing pharmaceutical compositions of an active indazole
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
AR036041A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
EP1425286B1 (de) * 2001-09-12 2007-02-28 Pharmacia & Upjohn Company LLC Substituierte 7-aza-[2.2.1]bicycloheptane für die behandlung von krankheiten
IL160884A0 (en) 2001-10-02 2004-08-31 Upjohn Co Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
JP2005523288A (ja) * 2002-02-19 2005-08-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾病治療用の縮合した二環式−ｎ−架橋−複素環式芳香族カルボキサミド
MXPA04008152A (es) * 2002-02-19 2005-09-08 Upjohn Co Compuestos azabiciclicos para el tratamiento de enfermedades.
EP1478646A1 (de) * 2002-02-20 2004-11-24 PHARMACIA & UPJOHN COMPANY Azabicyclische verbindungen mit activität an alfa7 nikotinischen acetylcholin rezeptoren
BR0315056A (pt) * 2002-11-01 2005-08-16 Pharmacia & Upjohn Co Llc Compostos tendo tanto atividade agonista nicotìnica de alfa7 quanto atividade antagonista de 5ht3 para o tratamento de doenças do sistema nervoso central
GB201421161D0 (en) * 2014-11-28 2015-01-14 Ge Healthcare As Metal complex formulations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI74707C (fi) * 1982-06-29 1988-03-10 Sandoz Ag Foerfarande foer framstaellning av terapeutiskt anvaendbara alkylenoeverbryggade piperidylestrar eller -amider av bicykliska karboxylsyror.
JPS5936675A (ja) * 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト 二環性複素環式カルボン酸アザビシクロアルキルエステルまたはアミド
FR2557110B1 (fr) * 1983-12-23 1989-11-24 Sandoz Sa Nouveaux derives d'amines cycliques, leur preparation et leur utilisation comme medicaments
EP0189002B1 (de) * 1984-12-20 1993-03-03 Sandoz Ag Behandlung von Gastrointestinalkrankheiten durch Anwendung von 5-HT3-Antagonisten
CH667657A5 (de) * 1985-01-07 1988-10-31 Sandoz Ag Carbocyclische und heterocyclische carbonylmethylen- und methylpiperidine und -pyrrolidine.
US4605652A (en) * 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
EP0405617A3 (en) * 1985-03-14 1992-11-25 Beecham Group P.L.C. Medicaments for the treatment of anxiety
US4624961A (en) * 1985-04-17 1986-11-25 A. H. Robins Company, Incorporated Method for enhancing memory or correcting memory deficiency with arylamidopyrazolidines and arylamidodiazabicycloalkanes
EP0200444B1 (de) * 1985-04-27 1992-11-11 Beecham Group Plc Azabicyclononyl-indazol-carboxamid mit 5-HT-antagonistischer Wirkung
DE3687980T2 (de) * 1986-01-07 1993-06-17 Beecham Group Plc Indolderivate mit einer azabicyclischen seitenkette, verfahren zu ihrer herstellung, zwischenprodukte und pharmazeutische zusammensetzungen.
HU895334D0 (en) * 1986-07-30 1990-01-28 Sandoz Ag Process for the preparation of nasal pharmaceutical compositions
DE3801659A1 (de) * 1988-01-21 1989-07-27 Boehringer Ingelheim Kg Tetrahydropyridin - derivate
CA1332151C (en) * 1988-01-28 1994-09-27 Roman Amrein Use of a benzamide to treat cognitive disorder
EP0342558B1 (de) * 1988-05-16 1994-02-02 G.D. Searle & Co. 2-Amino-4,5-methylenadipinsäure-Verbindungen für die Behandlung von CNS-Erkrankungen
YU150489A (sh) * 1989-08-10 1992-12-21 W.L. Gore & Co. Gmbh. Uređaj za ispitivanje odevnih predmeta na nepromočivost
AU647754B2 (en) * 1989-10-16 1994-03-31 Hem Research, Inc. Diagnosis and treatment of neuro-cognitive disorders associated with systemic immunological malfunction
DK0456519T3 (da) * 1990-05-11 1994-11-07 Sankyo Co Piperidyloxy- og quinuclidinyloxyisoxazolderivater, deres fremstilling og deres terapeutiske anvendelse

Also Published As

Publication number Publication date
DE3752062T2 (de) 1997-09-11
EP0279990B1 (de) 1995-07-12
ES2074981T3 (es) 1995-10-01
DE3752062D1 (de) 1997-06-12
GR3017369T3 (en) 1995-12-31
JPS63277623A (ja) 1988-11-15
EP0279990A3 (en) 1990-11-28
EP0559297A1 (de) 1993-09-08
EP0551963A3 (en) 1993-09-01
ATE124865T1 (de) 1995-07-15
US4985437A (en) 1991-01-15
DE3751404T2 (de) 1995-12-21
ATE152623T1 (de) 1997-05-15
EP0551963A2 (de) 1993-07-21
JP2608079B2 (ja) 1997-05-07
EP0279990A2 (de) 1988-08-31
EP0559297B1 (de) 1997-05-07

Similar Documents

Publication Publication Date Title
DE3751404D1 (de) Verwendung von heterocyclischen Verbindungen zur Behandlung von Bewusstseinsstörungen.
BR9206500A (pt) Heterociclos contendo, nitrogênio tricíclico condensado como antagonistas de substancia receptora P
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
MY132229A (en) Indole derivatives as 5-ht receptor antagonist
DE3788057D1 (de) Verwendung von heterocyclischen Verbindungen zur Behandlung von Depressionen.
DE3780972D1 (de) Verwendung von spezifischen n-methyl-d-aspartat-rezeptor-antagonisten zur praevention und behandlung von neurodegeneration.
DE3650647D1 (de) Arzneimittel zur Behandlung von Anxietas
ES2111650T3 (es) Derivados aciclicos de etilenodiamina como antagonistas de receptores de la sustancia p.
MX9100308A (es) Derivados de quinuclidina
MX9203018A (es) Fluoroalcoxibencilamino-derivados de heterociclos nitrogenados.
ES8400409A1 (es) "un procedimiento de preparacion de nuevas carboxamidas heterociclicas".
DE69530933D1 (de) Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis
DE3689099D1 (de) Verwendung von angiotensin-converting-enzym-inhibitoren zur behandlung von atherosklerose, thrombose und der peripheren gefaesskrankheit.
DE3782028D1 (de) Verwendung von ketonderivaten zur behandlung von bewusstseinsstoerungen.
ATE182467T1 (de) Verwendung von antagonisten oder partiellen agonisten am 5-ht 1a-rezeptor zur behandlung und prävention von kognitiven störungen
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
DE3751362D1 (de) 5-Aryl-3H-1,2,4-triazol-3-one und ihre Verwendung als Antikonvulsiva.
ATE116851T1 (de) 5-aryl-3h-1,2,4-triazol-3-one und ihre verwendung in der behandlung neurodegenerativer beschwerden.
ES8502103A1 (es) Procedimiento para la obtencion de amidas del acido piperazin-1-il-acetico substituido
DE3586420D1 (de) Verwendung von dihydropyridinen zur behandlung und praevention von arteriosklerose.
DE3785555D1 (de) Verwendung von guaifenesin zur behandlung urologischer beschwerden.
ATE41662T1 (de) Derivate von dihydro-1h-pyrrolo(1,2-c>imidazol3,5-dion zur aktivierung des wahrnehmungsvermoegens.
DE68926222D1 (de) Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen
DE3683330D1 (de) Verwendung von imidazolinylaminoisoindolen und verwandten verbindungen zur behandlung von hyperglykaemie.
ATE100100T1 (de) Oxadiazole zur verwendung in der behandlung von dementia senilis.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition